EMBARK — Tezepelumab for COPD
Sponsored by AstraZeneca
Concept
This study evaluates the efficacy and safety of tezepelumab in adults with moderate-to-severe COPD who continue to experience exacerbations despite maintenance inhaler therapy.
Key Eligibility Criteria
Below are the main inclusion and exclusion criteria for this study. The full eligibility assessment will be discussed with you by our research team during screening.
Key Inclusion Criteria
- Age 40–80 years
- Physician-diagnosed COPD for ≥12 months
- Post-bronchodilator FEV1/FVC <0.70
- FEV1 between 20% and 70% predicted
- On triple inhaler therapy (ICS + LABA + LAMA) or appropriate dual therapy for ≥3 months
- ≥2 moderate COPD exacerbations OR ≥1 severe exacerbation in the last 12 months
- Blood eosinophils ≥150 cells/µL
- CAT score ≥15 indicating symptomatic COPD
Key Exclusion Criteria
- Pulmonary diseases other than COPD
- Current physician-diagnosed asthma
- Active respiratory infection
- Unstable cardiovascular disease
- Significant uncontrolled systemic disease
- Conditions that may interfere with study completion
Apply for this study
Fill out the form below to see if you qualify. Our research coordinators will contact you directly to discuss your eligibility — there's no obligation to participate.
Your information is kept confidential and only used for study eligibility purposes.
Advancing research, one participant at a time.
Clinical trials depend on volunteers like you. By participating, you gain access to potential new treatments while helping researchers discover safer, more effective therapies for everyone.
- Access to investigational treatments and expert medical care
- Close monitoring by our experienced research team
- Contribute to better treatments for future patients
- Confidential — your information is protected at every step